When asked about risks, Apogee's CEO identified a lack of focus—not clinical failure—as the primary threat. By concentrating resources on atopic dermatitis, a large but underserved market, the smaller company can execute faster and more effectively than larger, more diffuse competitors like Sanofi and Lilly.

Unlike large pharma where novel projects compete with established, safer alternatives, biotech startups derive immense power from their singular focus. The "live or die" mentality on a single hard problem forces teams to innovate and persevere through setbacks, which is essential for pushing true scientific boundaries.

Unlike ventures in established biological pathways, startups tackling novel biology must first prove a specific drug product can work. The primary question isn't about the platform's potential applications but whether a single, tangible therapeutic is viable. Focusing on a broad platform too early is a mistake.

A common pitfall for science-led companies is getting lost in the pursuit of academic perfection while forgetting the ultimate goal: developing a marketable product. Success requires shifting focus from perfect science to creating a product that is "good enough" to help patients, a mindset crucial for navigating the complexities of drug development.

Founders of platform technologies are often tempted to pursue many applications at once. A more effective strategy is to select and aggressively advance a single "beachhead program" to the clinic. This demonstrates the platform's value concretely, making it easier to attract funding and partners, while avoiding the dilution of resources.

For a platform company with wide-ranging technology, the key early struggle is focusing. It is critical to prioritize a single program to generate near-term data and change the cost of capital before realizing the platform's full potential.

The primary operational difference between biotech and big pharma isn't just budget size, but how resource constraints force radical prioritization. The entire biotech organization must align on three or four critical, needle-moving goals tied to the next financing catalyst, a level of focus often diffused in larger companies.

For companies with a core technology platform, the single most critical and common failure point is misidentifying the first clinical programs. This strategic error squanders capital and time, often proving fatal before the platform's full potential can be realized.

Once profitable, biotechs should transition from a high-risk R&D culture to a more business-oriented model. Biogen's persistent, high-risk pursuit of Alzheimer's drugs demonstrates a common failure to make this strategic shift, wasting capital and acting more like a startup than a mature business.